Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
February 12, 2025
A Revolution in Immunology: Creating New Possibilities with Oral Medicines
Arsalan Shabbir, MD, PhD, Vice President, Clinical Development
June 11, 2025
Powering Possibility Through Oral Medicines with Biologics-like Profiles
Nello Mainolfi, PhD, Founder, President and CEO
April 24, 2025
A New Era of Possibility: Addressing Coveted Undrugged Targets
Juliet Williams, PhD, Head of Research
Showing 43 news results
September 19, 2025
Dermatology Times: KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader
June 25, 2025
Boston Business Journal: Kymera signs $750M Gilead deal, announces $250M stock offering
June 25, 2025
FirstWord Pharma: Kymera snags Gilead as new partner, while Sanofi opts for next-gen IRAK4 degrader
June 5, 2025
Barron’s: Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial
June 4, 2025
BiotechTV: Kymera Therapeutics’ Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company’s STAT6 healthy volunteer data
June 2, 2025
Biopharma Dive: Kymera, with new data, takes early step toward a Dupixent-like pill
June 2, 2025
Endpoints News: Kymera unveils ‘exceptional’ Phase 1 data for its Dupixent-in-a-pill program
June 2, 2025
STAT News: Kymera reports early-stage success for drug meant to rival Sanofi and Regeneron’s Dupixent
Featured Presentations & Publications
September 17, 2025
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
October 27, 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
American College of Rheumatology (ACR) 2025